3 Results for "

expanded CD4 T cells

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "expanded CD4 T cells" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P3719
CAS No.: 2022956-48-3
Target:  

CCR

Research Areas:  

Inflammation/Immunology

MOG (35-55) amide, mouse, rat the terminal amidation form of the 35-55 fragment of the myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide (MOG (35-55) (HY-P1240)). MOG(35-55) amide, mouse, rat can be used for experimental autoimmune encephalomyelitis (EAE) modeling .
loading...
    loading...
Cat. No.: HY-P99809
CAS No.: 2254059-25-9
Synonyms: MK-1308

Target:  

CTLA-4

Research Areas:  

Cancer

Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
loading...
    loading...
Cat. No.: HY-P11490
Target:  

MDM-2/p53

Research Areas:  

Inflammation/Immunology Cancer

DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 +/CD8 + cytotoxic T cells and suppressing CD4 +/CD25 + regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .
loading...
    loading...